Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Ralph Lauren Corp (RL) Price & Performance

Mesoblast LimitedTrade
Ralph Lauren CorpTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Ralph Lauren Corp — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Ralph Lauren Corp trades at $368.77 (market cap $21.89B). The key difference: Ralph Lauren Corp is far larger — about 12.5× Mesoblast Limited's market cap, and Ralph Lauren Corp pays a 1.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Ralph Lauren Corp for 84 Days on average.

MESORL
Market Cap
$1.75B$21.89B
Volume
239,027481,617
Sector
HealthConsumer Cyclical
52-Week High
$20.96$414.25
52-Week Low
$13.19$309.29
Typical Hold Time
14 Days84 Days
Enterprise Value
$1.83B$22.95B
Dividend Yield
—1.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.

The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.

Ralph Lauren Corp

Ralph Lauren (RL) trades at $361.14, down 2.04% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.59 exceeding the $4.32 estimate. Revenue growth has accelerated from $6.2B in 2022 to $7.1B in 2025, while net income margins improved to 10.49%. Recent developments include global store expansion and sustainability initiatives under the Timeless by Design 2030 strategy.

RL presents a compelling investment case with strong profitability (37.54% ROE, 70.27% gross margins) and analyst consensus pointing to 26% upside to the $456.67 price target. However, the stock faces near-term technical headwinds and competitive pressures in the luxury apparel sector. The improving cash flow trajectory and dividend payments provide shareholder value support amid market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MESO

No sentiment data available yet.

RL
100% Buy0% Sell
Avg holding period · 84 Days

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →

About Ralph Lauren Corp

Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.

Read more on RL →